Drug Profile
MK 1220
Alternative Names: MK-1220Latest Information Update: 18 Jan 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 31 Dec 2008 Phase-I clinical trials in Hepatitis C in USA (unspecified route)